EX-99.3 4 a17-12126_1ex99d3.htm EX-99.3

Exhibit 99.3

Discussion and
Reconciliation of Non-
GAAP Financial Measures

March 31, 2017

(Unaudited)

Definitions

Adjusted Fixed Charge Coverage Adjusted EBITDA (defined below) divided by Fixed Charges (defined below). Adjusted Fixed Charge Coverage is a supplemental measure of liquidity and the Company’s ability to meet its interest payments on outstanding debt and pay dividends to its preferred stockholders, if applicable. The Company’s various debt agreements contain covenants that require the Company to maintain ratios similar to Adjusted Fixed Charge Coverage, and credit rating agencies utilize similar ratios in evaluating and determining the credit rating on certain debt instruments of the Company. Adjusted Fixed Charge Coverage is subject to the same limitations and qualifications as Adjusted EBITDA and Fixed Charges.

Consolidated Debt The carrying amount of bank line of credit and term loans, senior unsecured notes, mortgage debt and other debt, as reported in the Company’s consolidated financial statements.

Consolidated Gross Assets The carrying amount of total assets, excluding investments in and advances to the Company’s unconsolidated joint ventures (“JVs”), after adding back accumulated depreciation and amortization, as reported in the Company’s consolidated financial statements. Consolidated Gross Assets is a supplemental measure of the Company’s financial position, which, when used in conjunction with debt-related measures, enables both management and investors to analyze its leverage and to compare its leverage to that of other companies.

Consolidated Secured Debt Mortgage and other debt secured by real estate, as reported in the Company’s consolidated financial statements.

EBITDA and Adjusted EBITDA Earnings before interest, taxes, depreciation and amortization for the Company. Adjusted EBITDA is defined as EBITDA excluding impairments (recoveries), gains or losses from real estate dispositions, transaction-related items, loss on debt extinguishments, severance-related charges, litigation provision, gain upon consolidation of JV and foreign currency exchange gains (losses). The Company considers EBITDA and Adjusted EBITDA important supplemental measures to net income (loss) because they provide an additional manner in which to evaluate the Company’s operating performance. Net income (loss) is the most directly comparable U.S. generally accepted accounting principles (“GAAP”) measure to EBITDA and Adjusted EBITDA.

Financial Leverage Total Debt (defined below) divided by Total Gross Assets (defined below). Financial Leverage is a supplemental measure of the Company’s financial position, which enables both management and investors to analyze its leverage and to compare its leverage to that of other companies. The Company’s pro rata share information is calculated by applying its actual ownership percentage for the period and excludes debt funded by the Company to its JVs. The ratio of Consolidated Debt to Consolidated Gross Assets is the most directly comparable GAAP measure to Financial Leverage. The Company’s pro rata share of total debt from the Company’s unconsolidated JVs is not intended to reflect its actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.

Fixed Charges Total interest expense plus capitalized interest plus preferred stock dividends (if applicable). Fixed Charges is a supplemental measure of the Company’s interest payments on outstanding debt and dividends to preferred stockholders for purposes of presenting Fixed Charge Coverage and Adjusted Fixed Charge Coverage. Fixed Charges is subject to limitations and qualifications, as, among other things, it does not include all contractual obligations.

Funds Available for Distribution (“FAD”) FAD is defined as FFO as adjusted (defined below) after excluding the impact of the following: (i) amortization of acquired market lease intangibles, net, (ii) amortization of deferred compensation expense, (iii) amortization of deferred financing costs, net, (iv) straight-line rents, (v) non-cash interest and depreciation related to direct financing leases (“DFLs”) and lease incentive amortization (reduction of straight-line rents) and (vi) deferred revenues, excluding amounts amortized into rental income that are associated with tenant funded improvements owned/recognized by the Company and up-front cash payments made by tenants to reduce their contractual rents. Also, FAD: (i) is computed after deducting recurring capital expenditures, including leasing costs and second generation tenant and capital improvements, and (ii) includes lease restructure payments and adjustments to compute the Company’s share of FAD from its unconsolidated joint ventures and those related to CCRC non-refundable entrance fees. Adjustments for joint ventures are calculated to reflect the Company’s pro-rata share of both its consolidated and unconsolidated joint ventures. The Company reflects its share of FAD for unconsolidated joint ventures by applying its actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. The Company reflects its share for consolidated joint ventures in which it does not own 100% of the equity by adjusting its FAD to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods (see FFO below for further disclosure regarding our use of pro-rata share information and its limitations). Other REITs or real estate companies may use different methodologies for calculating FAD, and accordingly, the Company’s FAD may not be comparable to those reported by other REITs. Although the Company’s FAD computation may not be comparable to that of other REITs, management believes FAD provides a meaningful supplemental measure of the Company’s performance and is frequently used by analysts, investors, and other interested parties in the evaluation of the Company’s performance as a REIT. The Company believes FAD is an alternative run-rate earnings measure that improves the understanding of its operating results among investors and makes comparisons with: (i) expected results, (ii) results of previous periods and (iii) results among REITS more meaningful. FAD does not represent cash generated from operating activities determined in accordance with GAAP and is not necessarily indicative of cash available to fund cash needs as it excludes the following items which generally flow through the Company’s cash flows from operating activities: (i) adjustments for changes in working capital or the actual timing of the payment of income or expense items that are accrued in the period, (ii) transaction-related costs, (iii) litigation settlement expenses, (iv) severance-related expenses and (v) actual cash receipts from interest income recognized on loans receivable (in contrast to our FAD adjustment to exclude non-cash interest and depreciation related to our investments in direct financing leases). Furthermore, FAD is adjusted for recurring capital expenditures, which are generally not considered when determining cash flows from operations or liquidity. FAD is a non-GAAP supplemental financial measure and should not be considered as an alternative to net income (loss) determined in accordance with GAAP.

Funds From Operations (“FFO”), FFO as adjusted and Comparable FFO as adjusted The Company believes FFO applicable to common shares, diluted FFO applicable to common shares, and diluted FFO per common share are important supplemental non-GAAP measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. The term FFO was designed by the REIT industry to address this issue.

| 1

Definitions

FFO, as defined by the National Association of Real Estate Investment Trusts (“NAREIT”), is net income (loss) applicable to common shares (computed in accordance with GAAP), excluding gains or losses from sales of depreciable property, including any current and deferred taxes directly associated with sales of depreciable property, impairments of, or related to, depreciable real estate, plus real estate and other depreciation and amortization, and adjustments to compute the Company’s share of FFO and FFO as adjusted (see below) from joint ventures. Adjustments for joint ventures are calculated to reflect the Company’s pro-rata share of both our consolidated and unconsolidated joint ventures. The Company reflects its share of FFO for unconsolidated joint ventures by applying its actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. The Company’s reflects its share for consolidated joint ventures in which it does not own 100% of the equity by adjusting its FFO to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. The Company’s pro-rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect its proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying its actual ownership percentage for the period. The Company does not control the unconsolidated joint ventures, and the pro-rata presentations of reconciling items included in FFO (see above) do not represent its legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital. See NOI above for further discussion regarding the use of pro-rata share information and its limitations.

FFO does not represent cash generated from operating activities in accordance with GAAP, is not necessarily indicative of cash available to fund cash needs and should not be considered an alternative to net income (loss). The Company computes FFO in accordance with the current NAREIT definition; however, other REITs may report FFO differently or have a different interpretation of the current NAREIT definition from the Company’s.

In addition, the Company presents FFO before the impact of non-comparable items including, but not limited to, severance-related charges, litigation provisions, preferred stock redemption charges, impairments (recoveries) of non-depreciable assets, prepayment costs (benefits) associated with early retirement or payment of debt, foreign currency remeasurement losses (gains) and transaction-related items (“FFO as adjusted”). Prepayment costs (benefits) associated with early retirement of debt include the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of debt. Transaction-related items include expensed acquisition and pursuit costs and gains/charges incurred as a result of mergers and acquisitions and lease amendment or termination activities. Management believes that FFO as adjusted provides a meaningful supplemental measurement of the Company’s FFO run-rate and is frequently used by analysts, investors and other interested parties in the evaluation of our performance as a REIT. At the same time that NAREIT created and defined its FFO measure for the REIT industry, it also recognized that “management of each of its member companies has the responsibility and authority to publish financial information that it regards as useful to the financial community.” The Company believes stockholders, potential investors and financial analysts who review our operating performance are best served by an FFO run-rate earnings measure that includes, in addition to adjustments made to arrive at the NAREIT defined measure of FFO, other adjustments to net income (loss). FFO as adjusted is used by management in analyzing our business and the performance of the Company’s properties, and management believes it is important that stockholders, potential investors and financial analysts understand this measure used by management. The Company uses FFO as adjusted to: (i) evaluate our performance in comparison with expected results and results of previous periods, relative to resource allocation decisions, (ii) evaluate the performance of its management, (iii) budget and forecast future results to assist in the allocation of resources, (iv) assess its performance as compared with similar real estate companies and the industry in general and (v) evaluate how a specific potential investment will impact its future results. Other REITs or real estate companies may use different methodologies for calculating an adjusted FFO measure, and accordingly, the Company’s FFO as adjusted may not be comparable to those reported by other REITs.

In addition, the Company presents Comparable FFO as adjusted, which excludes FFO as adjusted from Quality Care Properties, Inc. (“QCP”) and interest expense related to debt repaid using proceeds from the spin-off, assuming these transactions occurred at the beginning of the period presented. Comparable FFO as adjusted allows management to evaluate the performance of the Company’s remaining real estate portfolio following the completion of the QCP spin-off.

Investment Represents: (i) the carrying amount of real estate assets and intangibles, after adding back accumulated depreciation and amortization less the value attributable to refundable entrance fee liabilities; and (ii) the carrying amount of direct financing leases (“DFLs”) and debt investments. Investment excludes land held for development and assets held for sale. Investment also includes the Company’s pro rata share of the real estate assets and intangibles held in the Company’s unconsolidated JVs, presented on the same basis. The Company’s pro rata share information is calculated by applying its actual ownership percentage for the period.

Net Debt Total Debt (defined below) less the carrying amount of cash and cash equivalents as reported in the Company’s consolidated financial statements and the Company’s pro rata share of cash and cash equivalents from the Company’s unconsolidated JVs. The Company’s pro rata share information is calculated by applying its actual ownership percentage for the period. Consolidated Debt is the most directly comparable GAAP measure to Net Debt. Net Debt is a supplemental measure of the Company’s financial position, which enables both management and investors to analyze its leverage and to compare its leverage to that of other companies.

Net Debt to Adjusted EBITDA Net Debt divided by Adjusted EBITDA is a supplemental measure of the Company’s ability to decrease its debt. Because the Company may not be able to use its cash to reduce its debt on a dollar-for-dollar basis, this measure may have material limitations.

Net Operating Income from Continuing Operations (“NOI”) and Cash NOI NOI and Cash NOI are non-GAAP supplemental financial measures used to evaluate the operating performance of real estate. The Company includes properties from its consolidated portfolio, as well as its pro-rata share of properties owned by its unconsolidated joint ventures in its NOI and Cash NOI. The Company believes providing this information assists investors and analysts in estimating the economic interest in its total portfolio of real estate. The Company’s pro-rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect its proportionate economic interest in the operating results of properties in its portfolio and is calculated by applying its actual ownership percentage for the period. The Company does not control the unconsolidated joint ventures, and the pro-rata presentations of revenues and expenses included in NOI (see below) do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.

| 2

Definitions

The presentation of pro-rata information has limitations, which include, but are not limited to, the following (i) the amounts shown on the individual line items were derived by applying our overall economic ownership interest percentage determined when applying the equity method of accounting and do not necessarily represent the Company’s legal claim to the assets and liabilities, or the revenues and expenses and (ii) other companies in our industry may calculate their pro-rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro-rata financial information should not be considered independently or as a substitute for the Company’s financial statements as reported under GAAP. The Company compensates for these limitations by relying primarily on its GAAP financial statements, using the pro-rata financial information as a supplement.

NOI is defined as rental and related revenues, including tenant recoveries, resident fees and services, and income from DFLs, less property level operating expenses; NOI excludes all other financial statement amounts included in net income (loss). Management believes NOI provides relevant and useful information because it reflects only income and operating expense items that are incurred at the property level and presents them on an unleveraged basis. Cash NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, non-refundable entrance fees, net of entrance fee amortization and lease termination fees (“adjustments”). Cash NOI is oftentimes also referred to as “Adjusted NOI.” The Company uses NOI and Cash NOI to make decisions about resource allocations, to assess and compare property level performance, and to evaluate its same property portfolio (“SPP”), as described below. The Company believes that net income (loss) is the most directly comparable GAAP measure to NOI. NOI should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect various excluded items. Further, the Company’s definition of NOI may not be comparable to the definition used by other REITs or real estate companies, as they may use different methodologies for calculating NOI.

Operating expenses generally relate to leased medical office and life science properties and senior housing RIDEA properties. The Company generally recovers all or a portion of its leased medical office and life science property expenses through tenant recoveries. The Company presents expenses as operating or general and administrative based on the underlying nature of the expense. Periodically, the Company reviews the classification of expenses between categories and make revisions based on changes in the underlying nature of the expenses.

Same Property Portfolio SPP NOI and Cash NOI information allows the Company to evaluate the performance of its property portfolio under a consistent population by eliminating changes in the composition of our portfolio of properties. The Company includes properties from its consolidated portfolio, as well as properties owned by its unconsolidated joint ventures in its SPP NOI and Cash NOI (see NOI above for further discussion regarding our use of pro-rata share information and its limitations). The Company identifies its SPP as stabilized properties that remained in operations and were consistently reported as leased properties or RIDEA properties for the duration of the year-over-year comparison periods presented, excluding assets held for sale. Accordingly, it takes a stabilized property a minimum of 12 months in operations under a consistent reporting structure to be included in its SPP. Newly acquired operating assets are generally considered stabilized at the earlier of lease-up (typically when the tenant(s) control(s) the physical use of at least 80% of the space) or 12 months from the acquisition date. Newly completed developments and redevelopments are considered stabilized at the earlier of lease-up or 24 months from the date the property is placed in service. SPP NOI excludes (i) certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis and (ii) entrance fees and related activity such as deferred expenses, reserves and management fees related to entrance fees. A property is removed from SPP when it is classified as held for sale, sold, placed into redevelopment or changes its reporting structure.

Secured Debt Ratio Total Secured Debt (defined below) divided by Total Gross Assets (defined below). Secured Debt Ratio is a supplemental measure of the Company’s financial position, which enables both management and investors to analyze its leverage and to compare its leverage to that of other companies. The ratio of Consolidated Secured Debt to Consolidated Gross Assets is the most directly comparable GAAP measure to Secured Debt Ratio. The Company’s pro rata share information is calculated by applying its actual ownership percentage for the period and excludes debt funded by the Company to its JVs. The Company’s pro rata share of Total Secured Debt from the Company’s unconsolidated JVs is not intended to reflect its actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.

Segments The Company’s portfolio is comprised of investments in the following healthcare segments: (i) senior housing triple-net (“SH NNN”), (ii) senior housing operating portfolio (“SHOP”), (iii) life science (iv) medical office and (v) other non-reportable segments (“Other”).

Total Debt Consolidated Debt plus the Company’s pro rata share of total debt from the Company’s unconsolidated JVs. Total Debt is a supplemental measure of the Company’s financial position, which enables both management and investors to analyze its leverage and to compare its leverage to that of other companies. The Company’s pro rata share information is calculated by applying its actual ownership percentage for the period and excludes debt funded by the Company to its JVs. The Company’s pro rata share of Total Debt from the Company’s unconsolidated JVs is not intended to reflect its actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.

Total Gross Assets Consolidated Gross Assets plus the Company’s pro rata share of total assets from the Company’s unconsolidated JVs, after adding back accumulated depreciation and amortization. Total Gross Assets is a supplemental measure of the Company’s financial position, which, when used in conjunction with debt-related measures, enables both management and investors to analyze its leverage and to compare its leverage to that of other companies. The Company’s pro rata share information is calculated by applying its actual ownership percentage for the period.

Total Rental and Operating Revenue Consolidated rental and operating revenue plus the Company’s pro rata share of rental and operating revenue from its unconsolidated JVs. Total rental and operating revenue is a supplemental measure used to evaluate the operating performance of its real estate. The Company’s pro rata share information is calculated by applying its actual ownership percentage for the period. The Company does not control the unconsolidated joint ventures, and the pro-rata presentations of rental and operating revenue do not represent its legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.

Total Secured Debt Consolidated Secured Debt plus the Company’s pro rata share of mortgage debt from the Company’s unconsolidated JVs. Total Secured Debt is a supplemental measure of the Company’s financial position, which enables both management and investors to analyze its leverage and to compare its leverage to that of other companies. The Company’s pro rata share information is calculated by applying its actual ownership percentage for the period and excludes debt funded by the Company to its JVs. The Company’s pro rata share of total debt from the Company’s unconsolidated JVs is not intended to reflect its actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.

| 3

Reconciliations

In thousands, except per share data

Funds From Operations

|  | Three Months Ended March 31, |
|  | 2017 |  | 2016 |
Net income applicable to common shares |  | $ | 460,375 |  | $ | 115,762 |
Depreciation and amortization |  | 136,554 |  | 141,322 |
Other depreciation and amortization(1) |  | 3,010 |  | 2,962 |
Gain on sales of real estate, net |  | (317,258 | ) | — |
Taxes associated with real estate dispositions(2) |  | (5,499 | ) | 53,177 |
Equity (income) loss from unconsolidated joint ventures |  | (3,269 | ) | 908 |
FFO from unconsolidated joint ventures |  | 18,308 |  | 10,378 |
Noncontrolling interests’ and participating securities’ share in earnings |  | 3,802 |  | 3,983 |
Noncontrolling interests’ and participating securities’ share in FFO |  | (7,774 | ) | (9,226 | )
FFO applicable to common shares |  | $ | 288,249 |  | $ | 319,266 |
Distributions on dilutive convertible units |  | 2,803 |  | 3,583 |
Diluted FFO applicable to common shares |  | $ | 291,052 |  | $ | 322,849 |
Weighted average shares used to calculate diluted FFO per share |  | 475,173 |  | 472,186 |
Impact of adjustments to FFO: |  |  |  |  |
Other impairment recovery(3) |  | $ | (50,895 | ) | $ | — |
Transaction-related items(4) |  | 1,057 |  | 2,518 |
Litigation provision |  | 1,838 |  | — |
Foreign currency remeasurement gains |  | (77 | ) | — |
|  | $ | (48,077 | ) | $ | 2,518 |
FFO as adjusted applicable to common shares |  | $ | 240,172 |  | $ | 321,784 |
Distributions on dilutive convertible units and other |  | 2,877 |  | 3,579 |
Diluted FFO as adjusted applicable to common shares |  | $ | 243,049 |  | $ | 325,363 |
Weighted average shares used to calculate diluted FFO as adjusted per share |  | 475,173 |  | 472,186 |
FFO as adjusted from QCP |  | $ | — |  | $ | 98,207 |
Diluted Comparable FFO as adjusted applicable to common shares |  | $ | 243,049 |  | $ | 227,156 |
Diluted earnings per common share |  | $ | 0.97 |  | $ | 0.25 |
Depreciation and amortization |  | 0.29 |  | 0.30 |
Other depreciation and amortization |  | 0.01 |  | 0.01 |
Gain on sales of real estate, net and taxes related to real estate dispositions and |  | (0.68 | ) | 0.11 |
Joint venture and participating securities FFO adjustments |  | 0.02 |  | 0.01 |
Diluted FFO applicable to common shares |  | $ | 0.61 |  | $ | 0.68 |
Other impairment recovery |  | (0.10 | ) | — |
Transaction-related items and other |  | — |  | 0.01 |
FFO as adjusted applicable to common shares |  | $ | 0.51 |  | $ | 0.69 |
FFO as adjusted from QCP per common share |  | — |  | 0.21 |
Diluted Comparable FFO as adjusted per common share |  | $ | 0.51 |  | $ | 0.48 |

_________________________

(1) Other depreciation and amortization includes DFL depreciation and lease incentive amortization (reduction of straight-line rents) for the consideration given to terminate the 30 purchase options on the 153-property amended lease portfolio in the 2014 Brookdale transaction.

(2) For the three months ended March 31, 31 2017, represents income tax benefit associated with the disposition of real estate assets in the Company’s RIDEA II transaction. For the three months ended March 31, 2016, represents income tax expense associated with state built-in gain tax payable upon the disposition of specific real estate assets, of which $49 million relates to the HCR ManorCare, Inc. real estate portfolio

(3) Relates to the sale of the Company’s Four Seasons senior notes.

(4) On January 1, 2017, the Company early adopted the FASB ASU No. 2017-01, Clarifying the Definition of a Business, which prospectively results in recognizing the majority of its real estate acquisitions as asset acquisitions rather than business combinations. Acquisition and pursuit costs relating to completed asset acquisitions are capitalized, including those costs incurred prior to January 1, 2017. Real estate acquisitions completed prior to January 1, 2017 were deemed business combinations and the related acquisition and pursuit costs were expense as incurred.

| 4

Reconciliations

In thousands

Funds Available for Distribution

|  | Three Months Ended March 31, |
|  | 2017 |  | 2016 |
FFO as adjusted applicable to common shares |  | $ | 240,172 |  | $ | 321,784 |
Amortization of deferred compensation |  | 3,765 |  | 5,345 |
Amortization of deferred financing costs |  | 3,858 |  | 5,280 |
Straight-line rents |  | (5,007 | ) | (7,576 | )
Other depreciation and amortization |  | (3,010 | ) | (2,962 | )
Leasing costs and tenant and capital improvements(1) |  | (23,287 | ) | (20,482 | )
Lease restructure payments |  | 540 |  | 6,294 |
CCRC entrance fees(2) |  | 3,649 |  | 5,502 |
Deferred income taxes |  | (2,374 | ) | (2,942 | )
Other FAD adjustments |  | 249 |  | (1,205 | )
FAD applicable to common shares |  | $ | 218,555 |  | $ | 309,038 |
Distributions on dilutive convertible units |  | 2,803 |  | 3,583 |
Diluted FAD applicable to common shares |  | $ | 221,358 |  | $ | 312,621 |

_________________________

(1) Includes the Company’s share of leasing costs and tenant and capital improvements from unconsolidated joint ventures.

(2) Represents the Company’s 49% share of non-refundable entrance fees as the fees are collected by our CCRC JV, net of CCRC JV entrance fee amortization.

| 5

Reconciliations

Projected Future Operations(1)

|  | Full Year 2017 |
|  | Low |  | High |
Diluted earnings per common share |  | $ 1.43 |  | $ 1.49 |
Depreciation and amortization |  | 1.13 |  | 1.13 |
Other depreciation and amortization |  | 0.02 |  | 0.02 |
Gain on sales of real estate, net |  | (0.69) |  | (0.69) |
Taxes associated with real estate dispositions |  | (0.01) |  | (0.01) |
Joint venture FFO adjustments |  | 0.11 |  | 0.11 |
Diluted FFO per common share |  | $ 1.99 |  | $ 2.05 |
Other impairment recovery |  | (0.11) |  | (0.11) |
Transaction-related items and other |  | 0.01 |  | 0.01 |
Diluted FFO as adjusted per common share |  | $ 1.89 |  | $ 1.95 |

_________________________

(1) The foregoing projections reflect management’s view as of May 2, 2017 of current and future market conditions, including assumptions with respect to rental rates, occupancy levels, development items, and the earnings impact of the events referenced in the Company’s earnings press release for the quarter ended March 31, 2017 that was issued on May 2, 2017. These projections do not reflect the impact of unannounced future transactions, except as described herein, other impairments or recoveries, the future bankruptcy or insolvency of the Company’s operators, lessees, borrowers or other obligors, the effect of any future restructuring of its contractual relationships with such entities, gains or losses on marketable securities, ineffectiveness related to our cash flow hedges, or larger than expected litigation settlements and related expenses related to existing or future litigation matters. The Company’s actual results may differ materially from the projections set forth above. The aforementioned ranges represent management’s best estimates based upon the underlying assumptions as of May 2, 2017. Except as otherwise required by law, management assumes no, and hereby disclaims any, obligation to update any of the foregoing projections as a result of new information or new or future developments.

| 6

Reconciliations

In thousands

Projected Cash NOI Plus Interest Income, SPP NOI and SPP Cash NOI(1)

For the projected full year 2017 (low)

|  | SH NNN |  | SHOP |  | Life Science |  | Medical Office |  | Other |  | Total |
Cash NOI |  | $ | 322,500 |  | $ | 259,600 |  | $ | 275,000 |  | $ | 290,200 |  | $ | 114,200 |  | $ | 1,261,500 |
Interest income |  | — |  | — |  | — |  | — |  | 47,800 |  | 47,800 |
Cash NOI plus interest income |  | 322,500 |  | 259,600 |  | 275,000 |  | 290,200 |  | 162,000 |  | 1,309,300 |
Interest income |  | — |  | — |  | — |  | — |  | (47,800 | ) | (47,800 | )
Adjustments to cash NOI(2) |  | 400 |  | (18,200 | ) | (400 | ) | 4,100 |  | 4,200 |  | (9,900 | )
NOI |  | 322,900 |  | 241,400 |  | 274,600 |  | 294,300 |  | 118,400 |  | 1,251,600 |
Non-SPP NOI |  | (39,700 | ) | (49,050 | ) | (35,400 | ) | (41,500 | ) | (8,600 | ) | (174,250 | )
SPP NOI |  | 283,200 |  | 192,350 |  | 239,200 |  | 252,800 |  | 109,800 |  | 1,077,350 |
Adjustments to SPP NOI(2) |  | 5,600 |  | — |  | 5,100 |  | 1,200 |  | (4,100 | ) | 7,800 |
SPP cash NOI |  | $ | 288,800 |  | $ | 192,350 |  | $ | 244,300 |  | $ | 254,000 |  | $ | 105,700 |  | 1,085,150 |
Addback adjustments(3) |  |  |  |  |  |  |  |  |  |  |  | 166,450 |
Other income and expenses(4) |  |  |  |  |  |  |  |  |  |  |  | 377,400 |
Costs and expenses(5) |  |  |  |  |  |  |  |  |  |  |  | (947,700 | )
Net income |  |  |  |  |  |  |  |  |  |  |  | $ | 681,300 |

For the projected full year 2017 (high)

|  | SH NNN |  | SHOP |  | Life Science |  | Medical Office |  | Other |  | Total |
Cash NOI |  | $ | 326,600 |  | $ | 262,300 |  | $ | 277,900 |  | $ | 292,900 |  | $ | 115,400 |  | $ | 1,275,100 |
Interest income |  | — |  | — |  | — |  | — |  | 48,700 |  | 48,700 |
Cash NOI plus interest income |  | 326,600 |  | 262,300 |  | 277,900 |  | 292,900 |  | 164,100 |  | 1,323,800 |
Interest income |  | — |  | — |  | — |  | — |  | (48,700 | ) | (48,700 | )
Adjustments to cash NOI(2) |  | 500 |  | (18,400 | ) | (400 | ) | 4,100 |  | 4,200 |  | (10,000 | )
NOI |  | 327,100 |  | 243,900 |  | 277,500 |  | 297,000 |  | 119,600 |  | 1,265,100 |
Non-SPP NOI |  | (41,100 | ) | (49,700 | ) | (35,900 | ) | (41,700 | ) | (8,700 | ) | (177,100 | )
SPP NOI |  | 286,000 |  | 194,200 |  | 241,600 |  | 255,300 |  | 110,900 |  | 1,088,000 |
Adjustments to SPP NOI(2) |  | 5,600 |  | — |  | 5,100 |  | 1,200 |  | (4,150 | ) | 7,750 |
SPP cash NOI |  | $ | 291,600 |  | $ | 194,200 |  | $ | 246,700 |  | $ | 256,500 |  | $ | 106,750 |  | 1,095,750 |
Addback adjustments(3) |  |  |  |  |  |  |  |  |  |  |  | 169,350 |
Other income and expenses(4) |  |  |  |  |  |  |  |  |  |  |  | 384,900 |
Costs and expenses(5) |  |  |  |  |  |  |  |  |  |  |  | (940,200 | )
Net income |  |  |  |  |  |  |  |  |  |  |  | $ | 709,800 |

For the year ended December 31, 2016

|  | SH NNN |  | SHOP |  | Life Science |  | Medical Office |  | Other |  | Total |
Cash NOI |  | $ | 408,842 |  | $ | 263,828 |  | $ | 289,051 |  | 270,437 |  | $ | 119,629 |  | $ | 1,351,787 |
Interest income |  | — |  | — |  | — |  | — |  | 88,808 |  | 88,808 |
Cash NOI plus interest income |  | 408,842 |  | 263,828 |  | 289,051 |  | 270,437 |  | 208,437 |  | 1,440,595 |
Interest income |  | — |  | — |  | — |  | — |  | (88,808 | ) | (88,808 | )
Adjustments to cash NOI(2) |  | 7,566 |  | (20,076 | ) | 3,006 |  | 3,557 |  | 3,016 |  | (2,931 | )
NOI |  | 416,408 |  | 243,752 |  | 292,057 |  | 273,994 |  | 122,645 |  | 1,348,856 |
Non-SPP NOI |  | (136,315 | ) | (55,213 | ) | (53,805 | ) | (24,404 | ) | (14,759 | ) | (284,496 | )
SPP NOI |  | 280,093 |  | 188,539 |  | 238,252 |  | 249,590 |  | 107,886 |  | 1,064,360 |
Adjustments to SPP NOI(2) |  | (2,107 | ) | — |  | 114 |  | (547 | ) | (2,977 | ) | (5,517 | )
SPP cash NOI |  | $ | 277,986 |  | $ | 188,539 |  | $ | 238,366 |  | 249,043 |  | $ | 104,909 |  | 1,058,843 |
Addback adjustments(3) |  |  |  |  |  |  |  |  |  |  |  | 290,013 |
Other income and expenses(4) |  |  |  |  |  |  |  |  |  |  |  | 217,278 |
Costs and expenses(5) |  |  |  |  |  |  |  |  |  |  |  | (1,191,963 | )
Discontinued operations |  |  |  |  |  |  |  |  |  |  |  | 265,755 |
Net income |  |  |  |  |  |  |  |  |  |  |  | $ | 639,926 |

| 7

Reconciliations

Projected SPP NOI change for the full year 2017

|  | SH NNN |  | SHOP |  | Life Science |  | Medical Office |  | Other |  | Total |
Low |  | 1.1% |  | 2.0% |  | 0.4% |  | 1.3% |  | 1.8% |  | 1.2% |
High |  | 2.1% |  | 3.0% |  | 1.4% |  | 2.3% |  | 2.8% |  | 2.2% |

Projected SPP cash NOI change for the full year 2017

|  | SH NNN |  | SHOP |  | Life Science |  | Medical Office |  | Other |  | Total |
Low |  | 3.9% |  | 2.0% |  | 2.5% |  | 2.0% |  | 0.8% |  | 2.5% |
High |  | 4.9% |  | 3.0% |  | 3.5% |  | 3.0% |  | 1.8% |  | 3.5% |

_________________________

(1) The foregoing projections reflect management’s view as of May 2, 2017 of current and future market conditions, including assumptions with respect to rental rates, occupancy levels, development items, and the earnings impact of the events referenced in the Company’s earnings press release for the quarter ended March 31, 2017 that was issued on May 2, 2017. These projections do not reflect the impact of unannounced future transactions, except as described herein, other impairments or recoveries, the future bankruptcy or insolvency of the Company’s operators, lessees, borrowers or other obligors, the effect of any future restructuring of its contractual relationships with such entities, gains or losses on marketable securities, ineffectiveness related to our cash flow hedges, or larger than expected litigation settlements and related expenses related to existing or future litigation matters. The Company’s actual results may differ materially from the projections set forth above. The aforementioned ranges represent management’s best estimates based upon the underlying assumptions as of May 2, 2017. Except as otherwise required by law, management assumes no, and hereby disclaims any, obligation to update any of the foregoing projections as a result of new information or new or future developments.

(2) Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, lease termination fees and non-refundable entrance fees as the fees are collected by the Company’s CCRC JV, net of CCRC JV entrance fee amortization.

(3) Represents non-SPP NOI and adjustments to SPP NOI.

(4) Represents interest income, gain on sales of real estate, other income, net, income taxes and equity income (loss) from unconsolidated joint ventures, excluding NOI.

(5) Represents interest expense, depreciation and amortization, general and administrative expenses, acquisition and pursuit costs, and loss on debt extinguishments.

| 8

Reconciliations

In thousands

Total Gross Assets and Investment

|  | March 31, 2017 |
|  | SH NNN |  | SHOP |  | Life Science |  | Medical Office |  | Other |  | Corporate Non-Segment |  | Total |
Consolidated total assets |  | $ | 3,339,029 |  | $ | 2,832,432 |  | $ | 3,476,389 |  | $ | 2,931,722 |  | $ | 1,636,419 |  | $ | 639,877 |  | $ | 14,855,868 |
Investments in and advances to unconsolidated joint ventures |  | — |  | (746,853 | ) | (65,491 | ) | (13,478 | ) | (1,380 | ) | — |  | (827,202 | )
Accumulated depreciation and amortization net of assets held for sale |  | 719,274 |  | 347,707 |  | 781,237 |  | 952,404 |  | 186,330 |  | 92 |  | 2,987,044 |
Consolidated Gross Assets |  | $ | 4,058,303 |  | $ | 2,433,286 |  | $ | 4,192,135 |  | $ | 3,870,648 |  | $ | 1,821,369 |  | $ | 639,969 |  | $ | 17,015,710 |
HCP’s share of unconsolidated JV gross assets |  | — |  | 1,512,808 |  | 24,375 |  | 19,352 |  | 10,196 |  | — |  | 1,566,731 |
Total Gross Assets |  | $ | 4,058,303 |  | $ | 3,946,094 |  | $ | 4,216,510 |  | $ | 3,890,000 |  | $ | 1,831,565 |  | $ | 639,969 |  | $ | 18,582,441 |
Land held for development |  | — |  | — |  | (247,953 | ) | (947 | ) | (3,642 | ) | — |  | (252,542 | )
Fully depreciated real estate and intangibles excluding held for sale |  | 59,527 |  | 22,300 |  | 213,740 |  | 273,063 |  | 6,254 |  | — |  | 574,884 |
Non-real estate related assets(1) |  | (215,695 | ) | (486,236 | ) | (164,264 | ) | (157,718 | ) | (70,081 | ) | (639,969 | ) | (1,733,963 | )
Real estate intangible liabilities, net of held for sale |  | (45,227 | ) | (1,003 | ) | (97,960 | ) | (65,512 | ) | (25,513 | ) | — |  | (235,215 | )
Investment |  | $ | 3,856,908 |  | $ | 3,481,155 |  | $ | 3,920,073 |  | $ | 3,938,886 |  | $ | 1,738,583 |  | $ | — |  | $ | 16,935,605 |
Investment by type |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wholly-owned |  | 3,856,908 |  | 2,311,633 |  | 3,832,100 |  | 3,929,086 |  | 1,729,433 |  | — |  | 15,659,160 |
HCP’s share of unconsolidated JVs |  | — |  | 1,169,522 |  | 87,973 |  | 9,800 |  | 9,150 |  | — |  | 1,276,445 |
Investment |  | $ | 3,856,908 |  | $ | 3,481,155 |  | $ | 3,920,073 |  | $ | 3,938,886 |  | $ | 1,738,583 |  | $ | — |  | $ | 16,935,605 |

_________________________

(1) Includes straight-line rent receivables, net of reserves; lease commissions, net of amortization; cash and restricted cash; the value attributable to refundable entrance fee liabilities for the Company’s CCRC JV and other assets.

| 9

Reconciliations

In thousands

Total Rental and Operating Revenue

|  | Three Months Ended March 31, 2017 |
SH NNN |  | $ | 100,034 |
SHOP |  | 140,228 |
Life science |  | 85,321 |
Medical office |  | 118,371 |
Other |  | 29,883 |
Consolidated rental and operating revenue |  | $ | 473,837 |
SHOP |  | 76,364 |
Life science |  | 1,940 |
Medical office |  | 489 |
Other |  | 418 |
HCP’s share of unconsolidated JVs rental and operating revenue |  | $ | 79,211 |
SH NNN |  | 100,034 |
SHOP |  | 216,592 |
Life science |  | 87,261 |
Medical office |  | 118,860 |
Other |  | 30,301 |
Total rental and operating revenue |  | $ | 553,048 |

EBITDA and Adjusted EBITDA

|  | Three Months Ended March 31, 2017 |
Net income |  | $ | 464,177 |
Interest expense |  | 86,718 |
Income tax benefit |  | (6,162 | )
Depreciation and amortization |  | 136,554 |
Equity income from unconsolidated JVs |  | (3,269 | )
HCP’s share of unconsolidated JV EBITDA |  | 19,604 |
Other JV adjustments |  | (304 | )
EBITDA |  | $ | 697,318 |
Transaction-related items |  | 1,057 |
Other impairment recovery |  | (50,895 | )
Gain on sales of real estate, net |  | (317,258 | )
Litigation provision |  | 1,838 |
Foreign currency remeasurement gains |  | (77 | )
Adjusted EBITDA |  | $ | 331,983 |

| 10

Reconciliations

Dollars in thousands

Financial Leverage

|  | March 31, 2017 |
Total Debt |  | $ | 8,493,695 |
Total Gross Assets |  | 18,582,441 |
Financial Leverage |  | 45.7% |

Secured Debt Ratio

|  | March 31, 2017 |
Mortgage debt |  | $ | 147,329 |
HCP’s share of unconsolidated JV mortgage debt |  | 166,945 |
Secured debt |  | 314,274 |
Total Gross Assets |  | 18,582,441 |
Secured Debt Ratio |  | 1.7% |

Net Debt to Adjusted EBITDA

|  | March 31, 2017 |
Net Debt |  | $ | 7,692,935 |
Annualized Adjusted EBITDA(1) |  | 1,327,932 |
Net Debt to Adjusted EBITDA |  | 5.8x |

(1) Represents the current quarter Adjusted EBITDA multiplied by a factor of four.

| 11

Reconciliations

Dollars in thousands

Adjusted Fixed Charge Coverage

|  | Three Months Ended March 31, 2017 |
Adjusted EBITDA |  | $ | 331,983 |
Interest expense |  | 86,718 |
HCP’s share of unconsolidated JV interest expense |  | 1,388 |
Capitalized interest |  | 3,090 |
Fixed Charges |  | $ | 91,196 |
Adjusted Fixed Charge Coverage |  | 3.6x |

Total Debt and Net Debt

|  | March 31, 2017 |
Bank line of credit(1) |  | $ | 492,421 |
Term loan(2) |  | 274,103 |
Senior unsecured notes |  | 7,136,336 |
Mortgage debt |  | 147,329 |
Other debt |  | 91,263 |
Consolidated Debt |  | $ | 8,141,452 |
HCP’s share of unconsolidated JV mortgage debt |  | 166,945 |
HCP’s share of unconsolidated JV other debt |  | 185,298 |
Total Debt |  | $ | 8,493,695 |
Cash and cash equivalents |  | (764,114 | )
HCP’s share of unconsolidated JV cash and cash equivalents |  | (36,646 | )
Net Debt |  | $ | 7,692,935 |

(1) Represents £394 million translated into U.S. dollars (“USD”).

(2) Represents £220 million translated into USD.

| 12

Reconciliations

In thousands

Segment Cash NOI plus Interest Income and Same Property Performance

Total Consolidated

|  | Three Months Ended |
|  | March 31, 2016 |  | June 30 , 2016 |  | September 30, 2016 |  | December 31, 2016 |  | March 31, 2017 |
Net income |  | $ | 119,745 |  | $ | 304,842 |  | $ | 154,039 |  | $ | 61,300 |  | $ | 464,177 |
Interest income |  | (18,029 | ) | (32,787 | ) | (20,482 | ) | (17,510 | ) | (18,331 | )
Interest expense |  | 122,062 |  | 121,333 |  | 117,860 |  | 103,148 |  | 86,718 |
Depreciation and amortization |  | 139,855 |  | 139,919 |  | 141,407 |  | 146,927 |  | 136,554 |
General and administrative |  | 25,451 |  | 22,779 |  | 34,781 |  | 20,600 |  | 22,478 |
Acquisition and pursuit costs |  | 2,475 |  | 823 |  | 2,763 |  | 3,760 |  | 1,057 |
(Gain) loss on sales of real estate, net |  | — |  | (119,614 | ) | 9 |  | (45,093 | ) | (317,258 | )
Other (income) loss, net |  | (1,292 | ) | (2,340 | ) | (1,432 | ) | 1,410 |  | (51,208 | )
Loss on debt extinguishments |  | — |  | — |  | — |  | 46,020 |  | — |
Income tax expense (benefit) |  | 3,704 |  | (2,179 | ) | (424 | ) | 3,372 |  | (6,162 | )
Equity income (loss) from unconsolidated joint ventures |  | 908 |  | 1,067 |  | 2,053 |  | (15,388 | ) | (3,269 | )
Discontinued operations |  | (68,408 | ) | (107,375 | ) | (108,213 | ) | 18,246 |  | — |
HCP’s share of unconsolidated joint ventures: |  |  |  |  |  |  |  |  |  |  |
Revenues |  | 54,973 |  | 55,684 |  | 53,814 |  | 55,024 |  | 79,211 |
Operating expenses |  | (42,614 | ) | (43,035 | ) | (43,037 | ) | (42,137 | ) | (60,059 | )
NOI |  | $ | 338,830 |  | $ | 339,117 |  | $ | 333,138 |  | $ | 339,679 |  | $ | 333,908 |
Adjustment to NOI |  | (2,450 | ) | 2,008 |  | 1,337 |  | 2,050 |  | (568 | )
Cash NOI |  | $ | 336,380 |  | $ | 341,125 |  | $ | 334,475 |  | $ | 341,729 |  | $ | 333,340 |
Interest income |  | 18,029 |  | 32,787 |  | 20,482 |  | 17,510 |  | 18,331 |
Cash NOI plus interest income |  | $ | 354,409 |  | $ | 373,912 |  | $ | 354,957 |  | $ | 359,239 |  | $ | 351,671 |
Interest income |  | (18,029 | ) | (32,787 | ) | (20,482 | ) | (17,510 | ) | (18,331 | )
Adjustment to NOI |  | 2,450 |  | (2,008 | ) | (1,337 | ) | (2,050 | ) | 568 |
FX adjustment – GAAP SPP |  | (1,147 | ) | (1,183 | ) | (446 | ) | (11 | ) | — |
Non-SPP NOI |  | (58,481 | ) | (59,011 | ) | (56,805 | ) | (54,800 | ) | (47,579 | )
SPP NOI |  | $ | 279,202 |  | $ | 278,923 |  | $ | 275,887 |  | $ | 284,868 |  | $ | 286,329 |
Adjustment to SPP NOI |  | (6,151 | ) | (1,754 | ) | (869 | ) | (1,886 | ) | (2,246 | )
FX adjustment – Cash SPP |  | 133 |  | 125 |  | 45 |  | 2 |  | — |
SPP cash NOI |  | $ | 273,184 |  | $ | 277,294 |  | $ | 275,063 |  | $ | 282,984 |  | $ | 284,083 |

SH NNN

|  | Three Months Ended |
|  | March 31, 2016 |  | June 30 , 2016 |  | September 30, 2016 |  | December 31, 2016 |  | March 31, 2017 |
Net income |  | $ | 67,143 |  | $ | 92,890 |  | $ | 67,794 |  | $ | 91,688 |  | $ | 340,349 |
Interest expense |  | 4,166 |  | 4,049 |  | 644 |  | 640 |  | 627 |
Depreciation and amortization |  | 33,506 |  | 34,202 |  | 34,030 |  | 34,408 |  | 26,411 |
Gain on sales of real estate, net |  | — |  | (23,940 | ) | — |  | (24,804 | ) | (268,464 | )
NOI |  | $ | 104,815 |  | $ | 107,201 |  | $ | 102,468 |  | $ | 101,932 |  | $ | 98,923 |
Adjustment to NOI |  | (5,443 | ) | (2,018 | ) | (1,003 | ) | 898 |  | (1,839 | )
Cash NOI |  | $ | 99,372 |  | $ | 105,183 |  | $ | 101,465 |  | $ | 102,830 |  | $ | 97,084 |
Adjustment to NOI |  | 5,443 |  | 2,018 |  | 1,003 |  | (898 | ) | 1,839 |
Non-SPP NOI |  | (30,033 | ) | (31,809 | ) | (28,272 | ) | (24,724 | ) | (23,653 | )
SPP NOI |  | $ | 74,782 |  | $ | 75,392 |  | $ | 74,196 |  | $ | 77,208 |  | $ | 75,270 |
Adjustment to SPP NOI |  | (4,590 | ) | (1,200 | ) | (118 | ) | 493 |  | (1,515 | )
SPP cash NOI |  | $ | 70,192 |  | $ | 74,192 |  | $ | 74,078 |  | $ | 77,701 |  | $ | 73,755 |

| 13

Reconciliations

In thousands

SHOP

|  | Three Months Ended |
|  | March 31, 2016 |  | June 30 , 2016 |  | September 30, 2016 |  | December 31, 2016 |  | March 31, 2017 |
Net income |  | $ | 15,130 |  | $ | 13,446 |  | $ | 10,753 |  | $ | 32,967 |  | $ | 17,094 |
Interest expense |  | 7,855 |  | 7,837 |  | 8,130 |  | 5,928 |  | 4,596 |
Depreciation and amortization |  | 26,297 |  | 24,992 |  | 26,837 |  | 30,680 |  | 26,358 |
Gain on sales of real estate, net |  | — |  | — |  | — |  | (675 | ) | (366 | )
Equity income from unconsolidated joint ventures |  | 2,478 |  | 2,482 |  | 3,517 |  | (12,703 | ) | (1,993 | )
HCP’s share of unconsolidated joint ventures: |  |  |  |  |  |  |  |  |  |  |
Revenues |  | 52,277 |  | 52,855 |  | 50,973 |  | 52,167 |  | 76,364 |
Operating expenses |  | (42,088 | ) | (42,473 | ) | (42,463 | ) | (41,547 | ) | (59,527 | )
NOI |  | $ | 61,949 |  | $ | 59,139 |  | $ | 57,747 |  | $ | 66,817 |  | $ | 62,526 |
Adjustment to NOI |  | 5,032 |  | 5,537 |  | 4,608 |  | 4,900 |  | 3,508 |
Cash NOI |  | $ | 66,981 |  | $ | 64,676 |  | $ | 62,355 |  | $ | 71,717 |  | $ | 66,034 |
Adjustment to NOI |  | (5,032 | ) | (5,537 | ) | (4,608 | ) | (4,900 | ) | (3,508 | )
Non-SPP NOI |  | (13,198 | ) | (12,231 | ) | (13,407 | ) | (18,223 | ) | (12,372 | )
SPP NOI and cash NOI |  | $ | 48,751 |  | $ | 46,908 |  | $ | 44,340 |  | $ | 48,594 |  | $ | 50,154 |

Life Science

|  | Three Months Ended |
|  | March 31, 2016 |  | June 30 , 2016 |  | September 30, 2016 |  | December 31, 2016 |  | March 31, 2017 |
Net income |  | $ | 38,680 |  | $ | 69,762 |  | $ | 40,537 |  | $ | 55,892 |  | $ | 79,510 |
Interest expense |  | 638 |  | 632 |  | 634 |  | 453 |  | 104 |
Depreciation and amortization |  | 33,596 |  | 32,077 |  | 31,967 |  | 33,189 |  | 33,791 |
Gain on sales of real estate, net |  | — |  | (29,455 | ) | — |  | (19,614 | ) | (44,633 | )
Equity income from unconsolidated joint ventures |  | (709 | ) | (776 | ) | (778 | ) | (664 | ) | (770 | )
HCP’s share of unconsolidated joint ventures: |  |  |  |  |  |  |  |  |  |  |
Revenues |  | 1,810 |  | 1,898 |  | 1,929 |  | 1,971 |  | 1,940 |
Operating expenses |  | (374 | ) | (400 | ) | (406 | ) | (429 | ) | (371 | )
NOI |  | $ | 73,641 |  | $ | 73,738 |  | $ | 73,883 |  | $ | 70,798 |  | $ | 69,571 |
Adjustment to NOI |  | (673 | ) | (544 | ) | (314 | ) | (1,458 | ) | (256 | )
Cash NOI |  | $ | 72,968 |  | $ | 73,194 |  | $ | 73,569 |  | $ | 69,340 |  | $ | 69,315 |
Adjustment to NOI |  | 673 |  | 544 |  | 314 |  | 1,458 |  | 256 |
Non-SPP NOI |  | (9,135 | ) | (8,273 | ) | (8,534 | ) | (5,214 | ) | (2,473 | )
SPP NOI |  | $ | 64,506 |  | $ | 65,465 |  | $ | 65,349 |  | $ | 65,584 |  | $ | 67,098 |
Adjustment to SPP NOI |  | (59 | ) | 20 |  | 343 |  | (710 | ) | 347 |
SPP cash NOI |  | $ | 64,447 |  | $ | 65,485 |  | $ | 65,692 |  | $ | 64,874 |  | $ | 67,445 |

| 14

Reconciliations

In thousands

Medical Office

|  | Three Months Ended |
|  | March 31, 2016 |  | June 30 , 2016 |  | September 30, 2016 |  | December 31, 2016 |  | March 31, 2017 |
Net income |  | $ | 26,348 |  | $ | 33,684 |  | $ | 26,649 |  | $ | 29,880 |  | $ | 30,918 |
Interest expense |  | 1,665 |  | 1,625 |  | 1,608 |  | 995 |  | 129 |
Depreciation and amortization |  | 38,719 |  | 40,600 |  | 41,111 |  | 41,360 |  | 42,729 |
(Gain) loss on sales of real estate, net |  | — |  | (8,311 | ) | 9 |  | — |  | — |
Equity income from unconsolidated joint ventures |  | (658 | ) | (421 | ) | (462 | ) | (1,809 | ) | (269 | )
HCP’s share of unconsolidated joint ventures: |  |  |  |  |  |  |  |  |  |  |
Revenues |  | 479 |  | 524 |  | 502 |  | 492 |  | 489 |
Operating expenses |  | (149 | ) | (155 | ) | (148 | ) | (143 | ) | (142 | )
NOI |  | $ | 66,404 |  | $ | 67,546 |  | $ | 69,269 |  | $ | 70,775 |  | $ | 73,854 |
Adjustment to NOI |  | (795 | ) | (753 | ) | (814 | ) | (1,195 | ) | (969 | )
Cash NOI |  | $ | 65,609 |  | $ | 66,793 |  | $ | 68,455 |  | $ | 69,580 |  | $ | 72,885 |
Adjustment to NOI |  | 795 |  | 753 |  | 814 |  | 1,195 |  | 969 |
Non-SPP NOI |  | (2,327 | ) | (2,829 | ) | (4,323 | ) | (4,403 | ) | (7,710 | )
SPP NOI |  | $ | 64,077 |  | $ | 64,717 |  | $ | 64,946 |  | $ | 66,372 |  | $ | 66,144 |
Adjustment to SPP NOI |  | (810 | ) | (236 | ) | 45 |  | (576 | ) | (66 | )
SPP cash NOI |  | $ | 63,267 |  | $ | 64,481 |  | $ | 64,991 |  | $ | 65,796 |  | $ | 66,078 |

Other

|  | Three Months Ended |
|  | March 31, 2016 |  | June 30 , 2016 |  | September 30, 2016 |  | December 31, 2016 |  | March 31, 2017 |
Net income |  | $ | 39,785 |  | $ | 111,482 |  | $ | 40,365 |  | $ | 37,329 |  | $ | 41,736 |
Interest income |  | (18,029 | ) | (32,787 | ) | (20,482 | ) | (17,510 | ) | (18,331 | )
Interest expense |  | 2,327 |  | 2,476 |  | 2,260 |  | 2,084 |  | 1,997 |
Depreciation and amortization |  | 7,737 |  | 8,048 |  | 7,462 |  | 7,290 |  | 7,265 |
Gain on sales of real estate, net |  | — |  | (57,908 | ) | — |  | — |  | (3,795 | )
Equity income from unconsolidated joint ventures |  | (203 | ) | (218 | ) | (224 | ) | (212 | ) | (237 | )
HCP’s share of unconsolidated joint ventures: |  |  |  |  |  |  |  |  |  |  |
Revenues |  | 407 |  | 407 |  | 410 |  | 394 |  | 418 |
Operating expenses |  | (3 | ) | (7 | ) | (20 | ) | (18 | ) | (19 | )
NOI |  | $ | 32,021 |  | $ | 31,493 |  | $ | 29,771 |  | $ | 29,357 |  | $ | 29,034 |
Adjustment to NOI |  | (571 | ) | (214 | ) | (1,140 | ) | (1,095 | ) | (1,012 | )
Cash NOI |  | $ | 31,450 |  | $ | 31,279 |  | $ | 28,631 |  | $ | 28,262 |  | $ | 28,022 |
Interest income |  | 18,029 |  | 32,787 |  | 20,482 |  | 17,510 |  | 18,331 |
Cash NOI plus interest income |  | $ | 49,479 |  | $ | 64,066 |  | $ | 49,113 |  | $ | 45,772 |  | $ | 46,353 |
Interest income |  | (18,029 | ) | (32,787 | ) | (20,482 | ) | (17,510 | ) | (18,331 | )
Adjustment to NOI |  | 571 |  | 214 |  | 1,140 |  | 1,095 |  | 1,012 |
FX adjustment – GAAP SPP |  | (1,147 | ) | (1,183 | ) | (446 | ) | (11 | ) | — |
Non-SPP NOI |  | (3,788 | ) | (3,869 | ) | (2,269 | ) | (2,236 | ) | (1,371 | )
SPP NOI |  | $ | 27,086 |  | $ | 26,441 |  | $ | 27,056 |  | $ | 27,110 |  | $ | 27,663 |
Adjustment to SPP NOI |  | (692 | ) | (338 | ) | (1,139 | ) | (1,093 | ) | (1,012 | )
FX adjustment – Cash SPP |  | 133 |  | 125 |  | 45 |  | 2 |  | — |
SPP cash NOI |  | $ | 26,527 |  | $ | 26,228 |  | $ | 25,962 |  | $ | 26,019 |  | $ | 26,651 |

| 15

Reconciliations

In thousands

Corporate Non-Segment

|  | Three Months Ended |
|  | March 31, 2016 |  | June 30 , 2016 |  | September 30, 2016 |  | December 31, 2016 |  | March 31, 2017 |
Net income |  | $ | (67,341 | ) | $ | (16,422 | ) | $ | (32,059 | ) | $ | (186,456 | ) | $ | (45,430 | )
Interest expense |  | 105,411 |  | 104,714 |  | 104,584 |  | 93,048 |  | 79,265 |
General and administrative |  | 25,451 |  | 22,779 |  | 34,781 |  | 20,600 |  | 22,478 |
Acquisition and pursuit costs |  | 2,475 |  | 823 |  | 2,763 |  | 3,760 |  | 1,057 |
Other (income) loss, net |  | (1,292 | ) | (2,340 | ) | (1,432 | ) | 1,410 |  | (51,208 | )
Loss on debt extinguishments |  | — |  | — |  | — |  | 46,020 |  | — |
Income tax expense (benefit) |  | 3,704 |  | (2,179 | ) | (424 | ) | 3,372 |  | (6,162 | )
Discontinued operations |  | (68,408 | ) | (107,375 | ) | (108,213 | ) | 18,246 |  | — |
NOI |  | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | — |

Pro Forma Segment Cash NOI plus Interest Income

|  | March 31, 2017 |
|  | Cash NOI and Interest Income |  | Pro Forma Adjustments(1) |  | Pro Forma Cash NOI and Interest Income |
SH NNN |  | $ | 97,084 |  | $ | (22,635 | ) | $ | 74,449 |
SHOP |  | 66,034 |  | (1,766 | ) | 64,268 |
Life science |  | 69,315 |  | — |  | 69,315 |
Medical office |  | 72,885 |  | — |  | 72,885 |
Other |  | 46,353 |  | — |  | 46,353 |
|  | $ | 351,671 |  | $ | (24,401 | ) | $ | 327,270 |

(1) Current quarter Cash NOI and interest income pro forma to exclude the Cash NOI for 64 SH NNN properties sold in March 2017 and the sale of a 40% interest in RIDEA II that closed in January 2017.

| 16